Stable Isotope Labeling Kinetics of Human Tau in Alzheimer’s Disease

Principal Investigator

Washington University
St. Louis, MO
This grant is made possible by a bequest from the Estate of David and Annabel Ballard (The Ballard/Harvin Alzheimer’s Research Fund).

Project Goals

In Alzheimer’s disease, and amyloid protein called tau is increased in the brain and fluid that surrounds the brain. It is unclear why it is increased. Is this due to increased production or impaired clearance? How much is production or clearance altered? Can drugs be developed that can correct abnormal tau production or clearance? These questions can now be answered and the answers will give drugs that target tau a better chance of working against Alzheimer’s disease.

Project Summary

We have developed stable isotope labeling kinetics (SILK) methods to study the kinetics of proteins in the human central nervous system (CNS). With a tau SILK method, we will label participants with stable isotope amino acids and measure the amount of labeled tau that the brain produces over time. By measuring labeled tau, we will calculate how fast the brain produces tau and clears it away. In Aim 1, we will label young normal participants to study tau kinetics in a normal physiological state. In Aim 2, we will label participants with AD and age-matched cognitively normal controls to answer the question, do tau kinetics change in AD?

The past few decades of AD research have focused on amyloid-beta as the cause of AD, but today more evidence indicates that tau protein plays central roles in AD. Tau is mostly an intracellular protein but is also secreted as extracellular protein in normal conditions, and in increased amounts in AD. The SILK method that we pioneered is uniquely able to measure production and clearance of tau in humans. We believe our study elucidating the kinetics of tau in the human CNS will provide the first measures of why tau is increased in AD (i.e., through increased production versus impaired clearance).

Tau is an important biomarker of AD. Our study elucidating human CNS tau kinetics will enable better designs for prevention and treatment of AD in the future. Specifically, understanding why tau increases in AD will allow for better development of tau-targeted treatments. Our study will also greatly advance the understanding of basic tau biology.


Barthélemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TL, Buckles V, Fagan AM, Perrin RJ, Goate AM, Morris JC. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nature Medicine. 2020 Mar;26(3):398-407.  PMID: 32161412 PubMed Icon Google Scholar Icon

First published on: July 09, 2014

Last modified on: June 25, 2024